DermaVir, a novel HIV immunisation technology

  • Lori F
  • Trocio J
  • Bakare N
 et al. 
  • 21


    Mendeley users who have this article in their library.
  • 31


    Citations of this article.


DermaVir is a novel topical immunisation designed to target Langerhans cells (LC), the epidermal precursors of dendritic cells. LC serve as a vehicle to process and transfer antigens from the skin to T cell areas in the lymphoid organs. The HIV DNA delivered by DermaVir to LC expresses most viral regulatory and structural genes and induces T cell-mediated immune responses with broad specificity. In chronically infected macaques, DermaVir administered with antiretroviral drugs, suppressed viral load rebound after treatment interruption and improved survival. DermaVir is a promising antiretroviral treatment approach with a unique mechanism of action for combination with currently used drugs. © 2005 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • DermaVir
  • Therapeutic HIV immunisation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free